CoChat

Immune-infiltrated kidney organoid-on-chip model for assessing T cell bispecific antibodies

Open access

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Abstract

T cell bispecific antibodies (TCBs) are the focus of intense development for cancer immunotherapy. Recently, peptide-MHC (major histocompatibility complex)-targeted TCBs have emerged as a new class of biotherapeutics with improved specificity. These TCBs simultaneously bind to target peptides presented by the polymorphic, species-specific MHC encoded by the human leukocyte antigen (HLA) allele present on target cells and to the CD3 coreceptor expressed by human T lymphocytes. Unfortunately, traditional models for assessing their effects on human tissues often lack predictive capability, particularly for “on-target, off-tumor” interactions. Here, we report an immune-infiltrated, kidney organoid-on-chip model in which peripheral blood mononuclear cells (PBMCs) along with nontargeting (control) or targeting TCB-based tool compounds are circulated under flow. The target consists of the RMF peptide derived from the intracellular tumor antigen Wilms’ tumor 1 (WT1) presented on HLA-A2 via a bivalent T cell receptor-like binding domain. Using our model, we measured TCB-mediated CD8 + T cell activation and killing of RMF-HLA-A2-presenting cells in the presence of PBMCs and multiple tool compounds. DP47, a non-pMHC-targeting TCB that only binds to CD3 (negative control), does not promote T cell activation and killing. Conversely, the nonspecific ESK1-like TCB (positive control) promotes CD8 + T cell expansion accompanied by dose-dependent T cell–mediated killing of multiple cell types, while WT1-TCB* recognizing the RMF-HLA-A2 complex with high specificity, leads solely to selective killing of WT1-expressing cells within kidney organoids under flow. Our 3D kidney organoid model offers a platform for preclinical testing of cancer immunotherapies and investigating tissue-immune system interactions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.2305322120

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1. Immune-infiltrated kidney organoid-on-chip model for assessing TCBs. (A) Schematic illustration of the experimental setup. Organoids are seeded onto the millifluidic chip device on their day 11/12 of differentiation and cultured for 7 d under high flow culture conditions. On day 18/19 of kidney organoid differentiation, PBMCs are seeded into the millifluidic chip chamber, the TCB is added to the reservoir, and the chip is cultured under high flow culture conditions for 3 to 5 d until the readout assay is performed. (B) Schematic illustration of the mechanism of action of the TCB antibody: The TCB targets the effector cell, a CD8+ T cell to the cell of interest and the target cell is killed by release of cytolytic granules containing perforins and granzymes. (C) Human leukocyte antigen A2 (HLA-A2) expression quantified by flow cytometry analysis in kidney organoids cultured under high flow with (blue bars) or without (gray bars) 500 U/mL IFNγ for 3 d. **** indicates P < 0.0001 (D) Representative maximum intensity projections of confocal microscopy images showing the WT1 expression in the kidney organoids under high flow culture conditions in respect to the nephron structures of interest. The top left image in each panel is a representative bright-field image of the organoids structure, (scale bar for these grayscale images is 100 μm.) Podocalyxin (PODXL) labels podocytes, lotus tetranoglobus lectin (LTL) labels proximal tubules, E-Cadherin (CDH1) labels distal tubules, and Cluster of Differentiation 31 (CD31) labels endothelial cells. (Scale bar for the immunofluorescence images is 50 μm.) (E) Flow cytometry live/dead analysis of the CD45+ PBMC population under high flow compared to PBMCs in a static dish without organoids (Ctrl–Static). (F) Representative maximum intensity projections of confocal microscopy live images showing the PBMCs (labeled by CellMask™ Green) and the vasculature labeled by UEAI (red) in the kidney organoids under flow (upper image). The lower images show a 3D rendering of the same samples from a higher magnification image (G) Representative maximum intensity projections of confocal microscopy images showing the effect of adding TCBs and PBMCs to kidney organoids under high flow on chip. The kidney organoids in these conditions were cultured in the presence of either no TCB, a nontargeting TCB (DP47), or a targeting TCB (ESK1-like). The samples are stained for either nuclei (DAPI, blue), active caspases (FLICA, red), podocytes (PODXL, green), and proximal tubules (LTL, gray), or active caspases (FLICA, red), Wilms Tumor 1 (WT1, green), and cluster of differentiation (CD8, gray). The insets show either only the active caspases (FLICA, red) or the CD8 infiltration (CD8, gray). (Scale bars are 200 μm.)
Fig. 1. Immune-infiltrated kidney organoid-on-chip model for assessing TCBs. (A) Schematic illustration of the experimental setup. Organoids are seeded onto the millifluidic chip device on their day 11/12 of differentiation and cultured for 7 d under high flow culture conditions. On day 18/19 of kidney organoid differentiation, PBMCs are seeded into the millifluidic chip chamber, the TCB is added to the reservoir, and the chip is cultured under high flow culture conditions for 3 to 5 d until the readout assay is performed. (B) Schematic illustration of the mechanism of action of the TCB antibody: The TCB targets the effector cell, a CD8+ T cell to the cell of interest and the target cell is killed by release of cytolytic granules containing perforins and granzymes. (C) Human leukocyte antigen A2 (HLA-A2) expression quantified by flow cytometry analysis in kidney organoids cultured under high flow with (blue bars) or without (gray bars) 500 U/mL IFNγ for 3 d. **** indicates P < 0.0001 (D) Representative maximum intensity projections of confocal microscopy images showing the WT1 expression in the kidney organoids under high flow culture conditions in respect to the nephron structures of interest. The top left image in each panel is a representative bright-field image of the organoids structure, (scale bar for these grayscale images is 100 μm.) Podocalyxin (PODXL) labels podocytes, lotus tetranoglobus lectin (LTL) labels proximal tubules, E-Cadherin (CDH1) labels distal tubules, and Cluster of Differentiation 31 (CD31) labels endothelial cells. (Scale bar for the immunofluorescence images is 50 μm.) (E) Flow cytometry live/dead analysis of the CD45+ PBMC population under high flow compared to PBMCs in a static dish without organoids (Ctrl–Static). (F) Representative maximum intensity projections of confocal microscopy live images showing the PBMCs (labeled by CellMask™ Green) and the vasculature labeled by UEAI (red) in the kidney organoids under flow (upper image). The lower images show a 3D rendering of the same samples from a higher magnification image (G) Representative maximum intensity projections of confocal microscopy images showing the effect of adding TCBs and PBMCs to kidney organoids under high flow on chip. The kidney organoids in these conditions were cultured in the presence of either no TCB, a nontargeting TCB (DP47), or a targeting TCB (ESK1-like). The samples are stained for either nuclei (DAPI, blue), active caspases (FLICA, red), podocytes (PODXL, green), and proximal tubules (LTL, gray), or active caspases (FLICA, red), Wilms Tumor 1 (WT1, green), and cluster of differentiation (CD8, gray). The insets show either only the active caspases (FLICA, red) or the CD8 infiltration (CD8, gray). (Scale bars are 200 μm.)CC BY-NC-ND · PubMed Central
Fig. 2. Flow effects on ESK1-like TCB–mediated cell expansion and killing. (A) Fold change of %HLA-A2+ in the CD45- population analyzed by flow cytometry in the respective culture condition. Data are expressed as a fold change compared to Ctrl–no TCB and are normalized by the organoid area 1 d after seeding. Control samples and the “High Flow” condition are cultured under high flow; the “Low Flow” condition is cultured under low flow conditions. Control samples without the TCB, low flow, and high flow samples are culture with PBMCs, and low flow and high flow samples are cultured with PBMCs and TCBs. (B) Fold change of %CD8+ in the live CD45+ population in the respective culture condition. (C) Fold change of %HLA-DR+ in the CD8+ population (from B) in the respective culture condition. (D) Fold change in the live and dead CD45− negative cells compared to Ctrl–no TCB in the indicated culture conditions normalized by the organoid area 1 d after seeding. (E) Luminex assay data detecting Granzyme B in the culture medium supernatant of the respective culture condition. (F) LDH assay data of the TCB and T cell–mediated cell killing assay in the respective culture condition. (A–D and F) Fold change is normalized to the no TCB condition in each experiment to account for differences between donors. Asterisks indicate P-values in the one-way ANOVA with Tukey’s post-test as follows: *P < 0.0332, **P < 0.0021, ***P < 0.0002, ****P < 0.0001.
Fig. 2. Flow effects on ESK1-like TCB–mediated cell expansion and killing. (A) Fold change of %HLA-A2+ in the CD45- population analyzed by flow cytometry in the respective culture condition. Data are expressed as a fold change compared to Ctrl–no TCB and are normalized by the organoid area 1 d after seeding. Control samples and the “High Flow” condition are cultured under high flow; the “Low Flow” condition is cultured under low flow conditions. Control samples without the TCB, low flow, and high flow samples are culture with PBMCs, and low flow and high flow samples are cultured with PBMCs and TCBs. (B) Fold change of %CD8+ in the live CD45+ population in the respective culture condition. (C) Fold change of %HLA-DR+ in the CD8+ population (from B) in the respective culture condition. (D) Fold change in the live and dead CD45− negative cells compared to Ctrl–no TCB in the indicated culture conditions normalized by the organoid area 1 d after seeding. (E) Luminex assay data detecting Granzyme B in the culture medium supernatant of the respective culture condition. (F) LDH assay data of the TCB and T cell–mediated cell killing assay in the respective culture condition. (A–D and F) Fold change is normalized to the no TCB condition in each experiment to account for differences between donors. Asterisks indicate P-values in the one-way ANOVA with Tukey’s post-test as follows: *P < 0.0332, **P < 0.0021, ***P < 0.0002, ****P < 0.0001.CC BY-NC-ND · PubMed Central
Fig. 3. Dose-dependent response of ESK1-like TCB–mediated cell killing. (A) Fold change of %HLA-A2+ in the CD45− population exposed to either DP47 or ESK1-like TCB in the indicated concentration. (B) Luminex assay data on day 5 for IFNγ, IL-2, and TNFα in the respective culture condition. (C) Fold change of %CD8+ in the live CD45+ population in the respective culture condition. (D) Fold change of %CD69+, %CD25+, and %HLA-DR+ in the CD8+ population (from G) exposed to either DP47 or ESK1-like TCB in the indicated concentration. The Ctrl–no PBMC control is omitted, since those samples are not seeded with CD45+ cells. (E) Representative bright-field images on day 5 of the TCB-mediated cytotoxicity assay with the TCB concentration indicated on the image (white). (Scale bar is 500 μm.) (F) Representative 3D reconstruction of a confocal microscopy image showing CD8+ PRF1+ T cells (gray, magenta) near WT1+ Actin+ organoid cells. (Scale bar is 5 μm.) (G) Left: % live/dead cells in the CD45− population plotted in solid bars on the left y axis and total number of CD45− cells recovered from the sample plotted as dots on the right y axis exposed to either DP47 or ESK1-like TCB in the indicated concentration. Right: Fold change of the dead CD45− negative cells compared to Ctrl–no TCB in the indicated culture conditions normalized by the organoid area 1 d after seeding. (H) Luminex assay data on day 5 for Granzyme B in the respective culture condition. (I) LDH assay data for day 5 of the TCB cytotoxicity assay. Data are expressed as a fold change compared to Ctrl–no TCB and is normalized by the organoid area 1 d after seeding. (A, C, D, G, and I) Fold change is normalized to the no TCB condition in each experiment to account for differences between donors. Asterisks indicate P-values in the one-way ANOVA with Tukey’s post-test as follows: *P < 0.0332, **P < 0.0021, ***P < 0.0002, ****P < 0.0001.
Fig. 3. Dose-dependent response of ESK1-like TCB–mediated cell killing. (A) Fold change of %HLA-A2+ in the CD45− population exposed to either DP47 or ESK1-like TCB in the indicated concentration. (B) Luminex assay data on day 5 for IFNγ, IL-2, and TNFα in the respective culture condition. (C) Fold change of %CD8+ in the live CD45+ population in the respective culture condition. (D) Fold change of %CD69+, %CD25+, and %HLA-DR+ in the CD8+ population (from G) exposed to either DP47 or ESK1-like TCB in the indicated concentration. The Ctrl–no PBMC control is omitted, since those samples are not seeded with CD45+ cells. (E) Representative bright-field images on day 5 of the TCB-mediated cytotoxicity assay with the TCB concentration indicated on the image (white). (Scale bar is 500 μm.) (F) Representative 3D reconstruction of a confocal microscopy image showing CD8+ PRF1+ T cells (gray, magenta) near WT1+ Actin+ organoid cells. (Scale bar is 5 μm.) (G) Left: % live/dead cells in the CD45− population plotted in solid bars on the left y axis and total number of CD45− cells recovered from the sample plotted as dots on the right y axis exposed to either DP47 or ESK1-like TCB in the indicated concentration. Right: Fold change of the dead CD45− negative cells compared to Ctrl–no TCB in the indicated culture conditions normalized by the organoid area 1 d after seeding. (H) Luminex assay data on day 5 for Granzyme B in the respective culture condition. (I) LDH assay data for day 5 of the TCB cytotoxicity assay. Data are expressed as a fold change compared to Ctrl–no TCB and is normalized by the organoid area 1 d after seeding. (A, C, D, G, and I) Fold change is normalized to the no TCB condition in each experiment to account for differences between donors. Asterisks indicate P-values in the one-way ANOVA with Tukey’s post-test as follows: *P < 0.0332, **P < 0.0021, ***P < 0.0002, ****P < 0.0001.CC BY-NC-ND · PubMed Central
Fig. 4. Target specificity of WT1-TCB*-mediated cell killing. (A) Representative maximum intensity projections of confocal microscopy images of the kidney organoids on day 4 of the TCB-mediated cytotoxicity assay (from Z-stack videos in Movie S3). The samples were either cultured without (Left) or with the addition of 2 μg/mL WT1-TCB* (Right) and stained for active caspases (FLICA, gray), nuclei (DAPI, blue), CD8 T cells (CD8, green), and podocytes (PODXL, blue). (Scale bar is 20 μm.) (B) Expansion of CD8+ T cells in the live CD45+ population exposed to either ESK1-like TCB or WT1-TCB* in the indicated concentration (plot legend shown in (C)). (C) Fold change of %CD69+, and %CD25+ in the CD8+ population (from D) exposed to either ESK1-like TCB or WT1-TCB* in the indicated concentration. (D) Luminex assay data for Granzyme B, IFNγ, IL-2, and TNFα in the respective culture condition. (E) Fold change in the dead CD45− negative cells compared to Ctrl–no TCB in the indicated culture conditions normalized by the organoid area 1 d after seeding. (F) LDH assay data for days 1, 3, and 5 of the TCB cytotoxicity assay. Data are expressed as a fold change compared to Ctrl–no TCB and is normalized by the organoid area 1 d after seeding. (G) Proportion of the WT1high expressing cell populations either live (Left) or dead (Right) in the CD45− cell population exposed to either ESK1-like TCB or WT1-TCB* in the indicated concentration. (H) Proportion of the dead PODXL+, dead LTL+, dead HNF4A+, and dead CDH1+ cell populations in the CD45− cell population exposed to either ESK1-like TCB or WT1-TCB* in the indicated concentration. (I) Representative maximum intensity projections of confocal microscopy images of the kidney organoids on day 21 of differentiation cultured in static conditions showing WT1 (red) cells, proximal tubule cells (LTL, gray), nuclei (DAPI, blue), and distal tubule cells (CDH1, green). The white arrows indicate WT1+LTL+ cells. (Scale bar is 20 μm.) (J) Number of cells recovered from the live CD45- population that are either WT1 single positive (Left), WT1 and LTL double positive (Middle), or LTL single positive (Right). The samples are exposed to either ESK1-like TCB or WT1-TCB* in the indicated concentration. The number of cells is normalized by the organoid area 1 d after seeding. (B, E–H, and J) Fold change is normalized to the no TCB condition. Asterisks indicate P-values in the one-way ANOVA with Tukey’s post-test as follows: *P < 0.0332, **P < 0.0021, ***P < 0.0002, ****P < 0.0001.
Fig. 4. Target specificity of WT1-TCB*-mediated cell killing. (A) Representative maximum intensity projections of confocal microscopy images of the kidney organoids on day 4 of the TCB-mediated cytotoxicity assay (from Z-stack videos in Movie S3). The samples were either cultured without (Left) or with the addition of 2 μg/mL WT1-TCB* (Right) and stained for active caspases (FLICA, gray), nuclei (DAPI, blue), CD8 T cells (CD8, green), and podocytes (PODXL, blue). (Scale bar is 20 μm.) (B) Expansion of CD8+ T cells in the live CD45+ population exposed to either ESK1-like TCB or WT1-TCB* in the indicated concentration (plot legend shown in (C)). (C) Fold change of %CD69+, and %CD25+ in the CD8+ population (from D) exposed to either ESK1-like TCB or WT1-TCB* in the indicated concentration. (D) Luminex assay data for Granzyme B, IFNγ, IL-2, and TNFα in the respective culture condition. (E) Fold change in the dead CD45− negative cells compared to Ctrl–no TCB in the indicated culture conditions normalized by the organoid area 1 d after seeding. (F) LDH assay data for days 1, 3, and 5 of the TCB cytotoxicity assay. Data are expressed as a fold change compared to Ctrl–no TCB and is normalized by the organoid area 1 d after seeding. (G) Proportion of the WT1high expressing cell populations either live (Left) or dead (Right) in the CD45− cell population exposed to either ESK1-like TCB or WT1-TCB* in the indicated concentration. (H) Proportion of the dead PODXL+, dead LTL+, dead HNF4A+, and dead CDH1+ cell populations in the CD45− cell population exposed to either ESK1-like TCB or WT1-TCB* in the indicated concentration. (I) Representative maximum intensity projections of confocal microscopy images of the kidney organoids on day 21 of differentiation cultured in static conditions showing WT1 (red) cells, proximal tubule cells (LTL, gray), nuclei (DAPI, blue), and distal tubule cells (CDH1, green). The white arrows indicate WT1+LTL+ cells. (Scale bar is 20 μm.) (J) Number of cells recovered from the live CD45- population that are either WT1 single positive (Left), WT1 and LTL double positive (Middle), or LTL single positive (Right). The samples are exposed to either ESK1-like TCB or WT1-TCB* in the indicated concentration. The number of cells is normalized by the organoid area 1 d after seeding. (B, E–H, and J) Fold change is normalized to the no TCB condition. Asterisks indicate P-values in the one-way ANOVA with Tukey’s post-test as follows: *P < 0.0332, **P < 0.0021, ***P < 0.0002, ****P < 0.0001.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 2

  1. “ The Wilms’ Tumor (WT1)” in Gene Methods and Protocols, N. Hastie Ed. (Springer Science+Business Media, New York, NY, USA, 2016), vol. 1467, p. 235.
  2. K. T., Kroll., Dataset for Kroll, Mata, Homan et al. ‘Immune-infiltrated Kidney Organoid-on-Chip Model for Assessing T Cell Bispecific Antibodies’, PNAS, 2023. Materials Data Facility. 10.18126/E8Y5-AYFT. Deposited 24 July 2023. PMC10467620 37603766 · DOI

Cited by

See all 79

Metadata

Authors
Kroll, K. T., Mata, M. M., Homan, K. A., Micallef, V., Carpy, A., Hiratsuka, K., Morizane, R., Moisan, A., Gubler, M., Walz, A.-C., Marrer-Berger, E., & Lewis, J. A.
Affiliations
  • Harvard University (US)
  • F. Hoffmann-La Roche AG (CH)
  • Roche Pharma Research and Early Development, Roche Innovation Center Munich, Munich DE-82377, Germany
  • Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel CH-4070, Switzerland
Corresponding author
  • Homan, Kimberly A.
  • Lewis, Jennifer A.
Venue
Proceedings of the National Academy of Sciences
Published
2023-08-21
Volume
120
Issue
35
Pages
e2305322120-e2305322120
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W4386022662
Cited by
79
References
44
Citations by year
2026: 25 · 2025: 26 · 2024: 25 · 2023: 3
FWCI
6.24
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • Roche Pharma Research &amp; Early Development (N/A)
  • HHS | NIH | National Center for Advancing Translational Sciences (NIH UH3 Grant TR002155)
  • International Foundation of Ethical Research (N/A)
Topics
  • Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
T-cell bispecific antibodies, kidney organoids, organ-on-a-chip, HLA-A2, WT1 peptide, CD8+ T cell activation, T cell-mediated killing, on-target off-tumor toxicity, peripheral blood mononuclear cells, cancer immunotherapy, preclinical drug testing
MeSH terms
Humans, Kidney, Leukocytes, Mononuclear, Organoids, HLA-A2 Antigen, Antibodies, Bispecific

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.